The FDA study shows that the neutralizing potency of the antibody combination was within the range of neutralizing titers found in an individual previously infected with COVID-19.
The researchers sought to characterize the relationship between inflammatory markers and baseline, maximum, and change in troponin levels.
Researchers conducted a review of patients who were tested for COVID-19 and received aspirin or NSAIDS to assess whether aspirin was protective from death, myocardial infarction, or VTE.
The researchers conducted a comprehensive systematic review and meta-analysis comparing mortality and severe adverse events associated with receipt vs nonreceipt of ACEIs or ARBs among patients with COVID-19.
The US FDA inspected the Emergent BioSolutions plant, a subcontractor of Johnson & Johnson, which was manufacturing the Janssen COVID-19 vaccine and found several violations.
The researchers’ goals include systematically reviewing the existing evidence of cardiovascular involvement in infectious diseases, including tropical infectious diseases.
In today’s feature article, we talk with Ziyad Al-Aly, MD, of the Institute for Public Health in Washington, DC, who describes treating long-haulers as “America’s next big health crisis.”
Treatment with tocilizumab did not lead to improvement in clinical status and did not lower mortality at 28 days compared with placebo in hospitalized patients with severe pneumonia related to COVID-19.
Study authors examined the effect of high-dose zinc and/or ascorbic acid on the severity or reduction of SARS-CoV-2 duration compared with the standard of care.
Study authors reviewed challenges to COVID-19 access (production, affordability, allocation, and deployment), paths to success, and policy implications.
